IS TREATMENT-RESISTANCE IN PSYCHIATRIC DISORDERS A TRAP FOR POLYPHARMACY?

被引:0
|
作者
Jasovic-Gasic, Miroslava [1 ]
机构
[1] Univ Belgrade, Fac Med, Acad Med Sci, Serbian Med Soc, Belgrade 11000, Serbia
关键词
treatment resistance; polypharmacy; schizophrenia; psychiatric disorders; DOPAMINE SYNTHESIS CAPACITY; NEGATIVE SYMPTOMS; DOUBLE-BLIND; 2ND-GENERATION ANTIPSYCHOTICS; ELECTROCONVULSIVE-THERAPY; CHRONIC-SCHIZOPHRENIA; CLOZAPINE TREATMENT; CLINICAL-RESPONSE; METAANALYSIS; AUGMENTATION;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Nowadays, more and more mental health professionals manage patients who fail treatment for major psychiatric disorders. There is not a consensus on how to deal with treatment-resistance patients, but usually psychiatrists result to polypharmacy. Method: In reviewing the evidence based clinical research we will try to answer some questions about treatment-resistant psychiatric disorders. Treatment-resistant symptoms complicate the clinical course of all psychiatric disorders especially schizophrenia, causing the patients not to reach the therapeutical goal and enter remission. In consequence, polypharmacy is used to try to deal with the remaining symptoms, raising other issues. Summary: We will try to deal with this problematic issue through clinical studies and major research done to try and answer the question posed.
引用
收藏
页码:308 / 313
页数:6
相关论文
共 50 条
  • [1] Early Treatment-Resistance in First Episode Psychosis
    Fernando, Piyumi
    Strauss, Johanna
    Wagner, Elias
    Loehrs, Lisa
    Campana, Mattia
    Falkai, Peter
    Hasan, Alkomiet
    Papazova, Irina
    PHARMACOPSYCHIATRY, 2025, 58 (02) : 63 - 70
  • [2] Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders
    Nettis, Maria Antonietta
    BRAIN, BEHAVIOR, & IMMUNITY - HEALTH, 2021, 17
  • [3] Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders
    Medhekar, Rohan
    Aparasu, Rajender
    Bhatara, Vinod
    Johnson, Michael
    Alonzo, Joy
    Schwarzwald, Heidi
    Chen, Hua
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (04) : 395 - 403
  • [4] Oxytocin in the Treatment of Psychiatric Disorders
    Kagizman, Salim Cagatay
    Hocaoglu, Cicek
    MEDENIYET MEDICAL JOURNAL, 2023, 38 (03): : 218 - 231
  • [5] The Gut Microbiome and Treatment-Resistance in Schizophrenia
    Seeman, Mary V.
    PSYCHIATRIC QUARTERLY, 2020, 91 (01) : 127 - 136
  • [6] Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders
    Thompson, Joseph V.
    Clark, Joanne M.
    Legge, Sophie E.
    Kadra, Giouliana
    Downs, Johnny
    Walters, James T. R.
    Hamshere, Marian L.
    Hayes, Richard D.
    Taylor, David
    MacCabe, James H.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (05) : 436 - 443
  • [7] Antipsychotic Polypharmacy in the Treatment of Patients with Schizophrenia in Nine Psychiatric Hospitals of the Landschaftsverband Rheinland, Germany
    Schmidt-Kraepelin, Christian
    Meisenzahl-Lechner, Eva
    Kujovic, Milenko
    Cordes, Joachim
    Engelke, Christina
    Riesbeck, Mathias
    Zielasek, Jurgen
    Engemann, Sandra
    Vrinssen, Jurgem
    Lehmann, Isabell
    Tonnesen-Schlack, Anita
    Banger, Markus
    Grummer, Martine
    Scherbaum, Norbert
    Muysers, Jutta
    Rinckens, Stephan
    Marggraf, Ralph
    Gouzoulis-Mayfrank, Euphrosyne
    PSYCHIATRISCHE PRAXIS, 2021, 48 (05) : 250 - 257
  • [8] Neurostructural changes in schizophrenia and treatment-resistance: a narrative review
    Paul, Tanya
    See, Jia Whei
    Vijayakumar, Vetrivel
    Njideaka-Kevin, Temiloluwa
    Loh, Hanyou
    Lee, Vivian Jia Qi
    Dogrul, Bekir Nihat
    PSYCHORADIOLOGY, 2024, 4
  • [9] Psychiatric polypharmacy and electroconvulsive therapy in treatment-resistant depression
    Zoellner, Rebecca
    Huber, Martin T.
    Mangelsdorf, Constanze
    Konrad, Carsten
    Zavorotnyy, Maxim
    NERVENARZT, 2020, 91 (07): : 624 - 634
  • [10] The Gut Microbiome and Treatment-Resistance in Schizophrenia
    Mary V. Seeman
    Psychiatric Quarterly, 2020, 91 : 127 - 136